Abstract Number: 1247 • ACR Convergence 2022
Lung Ultrasound in Patients with Connective Tissue Disease-associated Interstitial Lung Disease; Utility of Single Evaluation in Clinical Practice
Background/Purpose: Utility of lung ultrasound (LUS) in evaluation of interstitial lung disease (ILD) has recently attracted attention because of handiness and low invasiveness. The majority…Abstract Number: 1858 • ACR Convergence 2022
A Multi-center Clinical Cohort Study of Chinese Anti-synthetase Syndrome Patients
Background/Purpose: Based on the Chinese Rheumatology Data Center Inflammatory Myopathy Registry (CRDC-MYO), this study aimed to describe the baseline characteristics of a subgroup of patients…Abstract Number: 2252 • ACR Convergence 2022
Higher Matrix Metalloproteinase Levels Are Predictive of Incident Interstitial Lung Disease Among a Cohort of US Veterans with Rheumatoid Arthritis
Background/Purpose: Matrix metalloproteinases (MMPs) degrade extracellular matrix and have been implicated to play a role in a number of fibrotic processes. Specifically, MMPs have been…Abstract Number: 0258 • ACR Convergence 2022
Rheumatoid Arthritis Associated Interstitial Lung Disease Across Continents
Background/Purpose: Interstitial lung disease (ILD) is a spectrum of inflammatory and fibrotic lung diseases, and can be associated with RA (RA-ILD). The reported prevalence in…Abstract Number: 1058 • ACR Convergence 2022
Clinical Characteristics and Survival of Combined Pulmonary Arterial Hypertension and Interstitial Lung Disease in Systemic Sclerosis
Background/Purpose: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are the leading causes of systemic sclerosis (SSc) associated death. There is increasing interest in…Abstract Number: 1393 • ACR Convergence 2022
Lung Involvement in Early Rheumatoid Arthritis, Interim Analysis of the FINDRA Prospective Study
Background/Purpose: The prevalence of lung involvement in rheumatoid arthritis (RA) remains elusive. We set up a prospective study to detect ILD, bronchiolitis and nodules in…Abstract Number: 1859 • ACR Convergence 2022
Urinary Beta-2 Microglobulin Is a Sensitive Prognostic Marker in Dermatomyositis Patients with Interstitial Lung Disease Positive for Anti-MDA-5 Antibody
Background/Purpose: Interstitial Lung Disease (ILD) accompanied with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is usually rapidly progressive and life-threatening with poor prognosis. Although…Abstract Number: 2253 • ACR Convergence 2022
Sputum Cytokines Are Elevated in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is a well-recognized comorbidity in rheumatoid arthritis (RA) that contributes significantly to morbidity and mortality. ILD is diagnosed in up…Abstract Number: 0003 • ACR Convergence 2022
Rituximab versus Cyclophosphamide for the Treatment of Connective Tissue Disease Associated Interstitial Lung Disease (RECITAL): A Sub-group Analysis of a Multi-centre Randomised Controlled Trial
Background/Purpose: The RECITAL trial (NCT01862926) compared rituximab to cyclophosphamide as first line therapy for patients with severe or progressive interstitial lung disease due to idiopathic…Abstract Number: 0438 • ACR Convergence 2022
Characterization of Interstitial Lung Disease in the Presence of Antineutrophil Cytoplasmic Antibodies
Background/Purpose: Various pulmonary manifestations may occur in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). ANCA-related interstitial lung disease (ILD) has recently been described in…Abstract Number: 1060 • ACR Convergence 2022
Clinical Characteristics and Prognosis of Patients with Systemic Sclerosis Sine Scleroderma: Data from the International EUSTAR Database
Background/Purpose: This study aimed to characterise the main clinical features of patients with systemic sclerosis (SSc) sine scleroderma (ssSSc) in comparison with the limited cutaneous…Abstract Number: 1520 • ACR Convergence 2022
Rituximab and Tocilizumab and Their Effect on Lung Disease Progression in Scleroderma. a Retrospective Cohort Study at a Single Centre
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of mortality in systemic sclerosis (SSc). Emerging evidence suggests a beneficial effect of tocilizumab…Abstract Number: 1874 • ACR Convergence 2022
Autoantibodies Are Common in Patients with Idiopathic Interstitial Lung Disease Suggesting a High Prevalence of Undiagnosed Autoimmune Connective Tissue Disease
Background/Purpose: In some patients, interstitial lung disease (ILD) may be the dominant or even sole overt manifestation of an otherwise unrecognised autoimmune connective tissue disease…Abstract Number: 0035 • ACR Convergence 2022
Anti-Peroxiredoxin 6 and Anti- Myosin Light Polypeptide 6 Autoantibodies with Interstitial Lung Disease and Severe Disease in Juvenile Dermatomyositis
Background/Purpose: Juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM) are among the most common forms of inflammatory rheumatic diseases in children. Anti-endothelial cell antibodies (AECA)…Abstract Number: 0508 • ACR Convergence 2022
Detecting the Critical Factors in the Pathogenesis of Anti-melanoma Differentiation-associated Gene 5–positive Dermatomyositis (MDA5 DM) by Gene Expression Analysis of Peripheral Blood
Background/Purpose: MDA5 DM is a distinct subtype of DM that is characterized by high mortality due to rapid progressive interstitial lung disease (ILD). MDA5 is…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 39
- Next Page »